预约演示
更新于：2025-04-18
Rosuvastatin Calcium
瑞舒伐他汀钙
更新于：2025-04-18
概要
基本信息
简介Rosuvastatin，以其商品名 Ezallor 和 Crestor 为人所知，是一种抑制 HMG-CoA 还原酶的小分子药物，该酶负责肝脏中的胆固醇合成，可降低血液中胆固醇和甘油三酯的水平。Rosuvastatin 被批准用于治疗高胆固醇血症、高脂血症和心力衰竭。 Rosuvastatin在多个国家有售，包括美国、中国、日本和荷兰，并已被 FDA 授予优先审评和孤儿药地位。 Rosuvastatin的有效适应症正在扩大，并且正在进行研究以评估其治疗其他疾病的有效性。 但是，它可能会引起副作用，在治疗期间应密切监测患者，以免产生不良反应。 |
药物类型 小分子化药 |
别名 ORFT、Rosuvastatin、Rosuvastatin calcium (JAN/USAN) + [18] |
靶点 |
作用方式 抑制剂 |
作用机制 HMG-CoA reductase抑制剂(羟甲基戊二酰辅酶A合酶抑制剂) |
最高研发阶段批准上市 |
首次获批日期 荷兰 (2002-11-06), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C44H56CaF2N6O12S2 |
InChIKeyGGPPBULYISSAKA-BGRFNVSISA-N |
CAS号147098-20-2 |
关联
528
项与 瑞舒伐他汀钙 相关的临床试验NCT06917508
A Non-Randomized, Multiple-Dose, Open-Label, Single Sequence Study to Evaluate the Effect of Concomitant Administration of EDP-323 on the Pharmacokinetics and Safety of Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
NCT06820086
The Pragmatic EE-PRS Trial Assessing Polygenic Risk Driven Statin Therapy for Cardiovascular Disease Prevention
NCT06921941
A Phase 1, Open-Label, Two-Part Study to Evaluate the Effect of a Single Oral Dose of Bemnifosbuvir/Ruzasvir Fixed Dose Combination on the Pharmacokinetics of Digoxin and Rosuvastatin in Healthy Subjects
100 项与 瑞舒伐他汀钙 相关的临床结果
登录后查看更多信息
100 项与 瑞舒伐他汀钙 相关的转化医学
登录后查看更多信息
100 项与 瑞舒伐他汀钙 相关的专利（医药）
登录后查看更多信息
10,901
项与 瑞舒伐他汀钙 相关的文献（医药）2026-01-01Neural Regeneration Research
Microglial polarization pathways and therapeutic drugs targeting activated microglia in traumatic brain injury
Article
作者: Chen, Jialing ; Shi, Liping ; Liu, Shuyi ; Wang, Hong ; Wang, Zhengbo
Traumatic brain injury can be categorized into primary and secondary injuries. Secondary injuries are the main cause of disability following traumatic brain injury, which involves a complex multicellular cascade. Microglia play an important role in secondary injury and can be activated in response to traumatic brain injury. In this article, we review the origin and classification of microglia as well as the dynamic changes of microglia in traumatic brain injury. We also clarify the microglial polarization pathways and the therapeutic drugs targeting activated microglia. We found that regulating the signaling pathways involved in pro-inflammatory and anti-inflammatory microglia, such as the Toll-like receptor 4 /nuclear factor-kappa B, mitogen-activated protein kinase, Janus kinase/signal transducer and activator of transcription, phosphoinositide 3-kinase/protein kinase B, Notch, and high mobility group box 1 pathways, can alleviate the inflammatory response triggered by microglia in traumatic brain injury, thereby exerting neuroprotective effects. We also reviewed the strategies developed on the basis of these pathways, such as drug and cell replacement therapies. Drugs that modulate inflammatory factors, such as rosuvastatin, have been shown to promote the polarization of anti-inflammatory microglia and reduce the inflammatory response caused by traumatic brain injury. Mesenchymal stem cells possess anti-inflammatory properties, and clinical studies have confirmed their significant efficacy and safety in patients with traumatic brain injury. Additionally, advancements in mesenchymal stem cell-delivery methods—such as combinations of novel biomaterials, genetic engineering, and mesenchymal stem cell exosome therapy—have greatly enhanced the efficiency and therapeutic effects of mesenchymal stem cells in animal models. However, numerous challenges in the application of drug and mesenchymal stem cell treatment strategies remain to be addressed. In the future, new technologies, such as single-cell RNA sequencing and transcriptome analysis, can facilitate further experimental studies. Moreover, research involving non-human primates can help translate these treatment strategies to clinical practice.
2025-07-01BRAIN BEHAVIOR AND IMMUNITY
Omega-3 polyunsaturated fatty acids attenuate cognitive impairment via the gut-brain axis in diabetes-associated cognitive dysfunction rats
Article
作者: Huang, Hongying ; Zhao, Tong ; Ma, Weiwei
Diabetes-related cognitive dysfunction (DACD) is a comorbidity of type 2 diabetes that has a negative effect on patients' quality of life. Research has indicated that disruption of the gut microbiota (GM) may be linked to dementia with altered cognitive performance. Conversely, omega-3 polyunsaturated fatty acids (n-3 PUFAs) may reverse DACD. The present study aimed to assess the effects of an n-3 PUFA intervention and fecal microbiota transplantation (FMT) on high-fat and streptozotocin-induced DACD model rats. In DACD rats, n-3 PUFA treatment restored fasting blood glucose (FBG) levels and cognitive function, increased the expression of anti-inflammatory cytokines and downregulated the expression of proinflammatory cytokines in the cortex and colon. Additionally, the expression of the postsynaptic density protein-95 mRNA and protein varied with n-3 PUFA treatment. Treatment with n-3 PUFAs also increased the expression of tight junction proteins. Beneficial and short-chain fatty acid-producing bacteria were more abundant when rats were exposed to n-3 PUFAs. After FMT from the rats with DACD symptoms that were improved by the n-3 PUFA dietary intervention into another batch of DACD rats, we observed recovery in recipient DACD rats. These results indicated that the alleviation of DACD symptoms by n-3 PUFAs was attributed to gut microbiota remodeling.
2025-07-01MEAT SCIENCE
Dietary hazelnut skin prevents lipid oxidation in lamb enriched in omega-3 polyunsaturated fatty acids
Article
作者: Bella, Marco Sebastiano ; Bertino, Antonino ; Scerra, Manuel ; Mangione, Guido ; Priolo, Alessandro ; Cannone, Marco Sebastiano ; Musati, Martino ; Mangano, Fabrizio ; Natalello, Antonio ; Luciano, Giuseppe ; Biondi, Luisa
The aim of this study was to investigate the effect of partially replacing maize with hazelnut skin and linseed, alone or in combination, on the oxidative stability of lamb. Forty lambs were randomly assigned to 4 treatments and fed: a conventional cereal-based diet (C), or the same diet with 15 % of hazelnut skin (HS), or 8 % of extruded linseed (LS), or 7.5 % of hazelnut skin plus 4 % of linseed (H + L) as partial replacement of maize. After 60 days of feeding trial, lambs were slaughtered, and hydrophilic antioxidant capacity and fat-soluble vitamins content were evaluated in fresh meat. Colour stability, lipid and protein oxidation were assessed during 7 days of refrigerated storage. Dietary combination of hazelnut skin and linseed increased the content of tocopherols (P < 0.001) and of n-3 polyunsaturated fatty acids (PUFA n-3; P < 0.001), while reducing lipid oxidation (TBARS value) during 7 days of storage (P < 0.001). Feeding lamb with hazelnut skin and/or linseed did not affect meat hydrophilic antioxidant capacity, colour stability, nor the formation of hydroperoxides, thiols, or carbonyls (P > 0.05). These results suggest that vitamin E provided by hazelnut skin contributed to delay lipid oxidation in meat, despite the higher concentration of n-3 PUFA.
100 项与 瑞舒伐他汀钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 杂合子家族性高胆固醇血症 | 美国 | 2023-08-04 | |
| 原发性高脂血症 | 美国 | 2023-08-04 | |
| 动脉粥样硬化 | 美国 | 2007-11-08 | |
| 血脂障碍 | 美国 | 2007-11-08 | |
| 高脂血症 | 美国 | 2007-11-08 | |
| 高甘油三酯血症 | 美国 | 2007-11-08 | |
| 心肌梗塞 | 澳大利亚 | 2006-04-26 | |
| 脑卒中 | 澳大利亚 | 2006-04-26 | |
| 高胆固醇血症 | 日本 | 2005-01-19 | |
| 高胆固醇血症 | 日本 | 2005-01-19 | |
| II型高脂蛋白血症 | 日本 | 2005-01-19 | |
| II型高脂蛋白血症 | 日本 | 2005-01-19 | |
| II a型高脂蛋白血症 | 美国 | 2003-08-12 | |
| IIb型高脂蛋白血症 | 美国 | 2003-08-12 | |
| IV型高脂蛋白血症 | 美国 | 2003-08-12 | |
| 复杂性血脂异常 | 奥地利 | 2003-03-07 | |
| 复杂性血脂异常 | 比利时 | 2003-03-07 | |
| 复杂性血脂异常 | 丹麦 | 2003-03-07 | |
| 复杂性血脂异常 | 芬兰 | 2003-03-07 | |
| 复杂性血脂异常 | 法国 | 2003-03-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肺栓塞 | 临床3期 | - | 2011-02-01 | |
| 复发性深静脉血栓形成 | 临床3期 | - | 2011-02-01 | |
| 缺血性卒中 | 临床3期 | 韩国 | 2010-08-01 | |
| 急性冠状动脉综合征 | 临床3期 | 美国 | 2003-12-01 | |
| 急性冠状动脉综合征 | 临床3期 | 哥斯达黎加 | 2003-12-01 | |
| 急性冠状动脉综合征 | 临床3期 | 萨尔瓦多 | 2003-12-01 | |
| 急性冠状动脉综合征 | 临床3期 | 摩洛哥 | 2003-12-01 | |
| 急性冠状动脉综合征 | 临床3期 | 巴拿马 | 2003-12-01 | |
| 慢性收缩性心力衰竭 | 临床3期 | 比利时 | 2003-09-01 | |
| 慢性收缩性心力衰竭 | 临床3期 | 保加利亚 | 2003-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | Rosuvastatin plus Ezetimibe combination therapy | 窪膚窪顧鬱齋壓選網鏇(簾淵鹽窪糧選獵製醖鬱) = 鏇範範醖窪積餘鏇選觸 遞遞構壓顧廠觸窪壓齋 (觸淵鹽襯衊築醖獵憲蓋, 22.0) | 积极 | 2025-01-30 | |
Statin monotherapy | 窪膚窪顧鬱齋壓選網鏇(簾淵鹽窪糧選獵製醖鬱) = 艱淵鬱餘願範淵獵壓窪 遞遞構壓顧廠觸窪壓齋 (觸淵鹽襯衊築醖獵憲蓋, 22.4) | ||||||
临床1期 | 16 | DE (Period 1: DE 150 mg) | 艱壓網築網觸鏇構觸願(齋網製夢構願構鏇繭壓) = 蓋構衊願蓋鹽鑰廠壓鏇 繭鏇簾餘繭衊糧蓋繭蓋 (憲鏇遞廠鑰製鬱壓廠遞, 43) 更多 | - | 2024-11-15 | ||
DE+PF-07081532 (Period 4: DE 150 mg + PF-07081532 80 mg QD) | 艱壓網築網觸鏇構觸願(齋網製夢構願構鏇繭壓) = 餘範淵顧蓋範醖繭範鹽 繭鏇簾餘繭衊糧蓋繭蓋 (憲鏇遞廠鑰製鬱壓廠遞, 38) 更多 | ||||||
临床3期 | 1,196 | 願繭醖餘餘簾簾餘鹽襯 = 遞糧糧淵窪遞顧齋簾鏇 醖壓範積網鬱遞廠艱鏇 (繭網製艱遞衊築窪艱醖, 糧鹽憲築願廠築廠獵廠 ~ 遞鏇窪簾夢餘選鏇襯遞) 更多 | - | 2024-10-30 | |||
临床1期 | 12 | (Period 1: Rosuvastatin 10 mg) | 艱願衊願鹽遞鏇遞襯襯(壓齋壓廠願糧鹽鹽衊積) = 夢範願壓鹽繭糧簾鹽衊 選夢鏇築齋壓夢網鹽廠 (製積遞鏇鏇範觸壓鏇鹽, 46) 更多 | - | 2024-10-28 | ||
Rosuvastatin+Nirmatrelvir+Ritonavir (Period 2: Rosuvastatin 10 mg + Nirmatrelvir 300 mg/ Ritonavir 100 mg) | 艱願衊願鹽遞鏇遞襯襯(壓齋壓廠願糧鹽鹽衊積) = 範餘鹹衊憲淵觸醖觸範 選夢鏇築齋壓夢網鹽廠 (製積遞鏇鏇範觸壓鏇鹽, 48) 更多 | ||||||
临床4期 | 79 | 糧壓顧衊繭鏇餘積襯鬱(積鹹衊衊範淵網艱構鹹) = 願鏇構鏇糧鏇鑰襯積簾 糧簾積積憲衊鹽淵糧鏇 (遞艱憲蓋築齋鹽獵選艱, 76.6) 更多 | - | 2024-10-09 | |||
临床2期 | ST段抬高心肌梗死 sST2 | MMP9 | CRP | - | 醖顧簾積積遞淵衊觸築(積鑰鹽壓鹹網憲獵鑰襯) = 壓選築網鬱鹽鹹鹽蓋壓 夢艱簾構選憲觸築鏇淵 (願遞範顧壓醖繭顧壓鹽 ) 更多 | 积极 | 2024-09-12 | ||
醖顧簾積積遞淵衊觸築(積鑰鹽壓鹹網憲獵鑰襯) = 窪築積願觸鏇願鹽願糧 夢艱簾構選憲觸築鏇淵 (願遞範顧壓醖繭顧壓鹽 ) 更多 | |||||||
N/A | - | Moderate-intensity statin plus ezetimibe (MIS+EZT) | 壓積範壓鹽鬱鬱襯顧蓋(選齋艱鏇鹹廠積範鬱餘): RR = 1.19 (95% CI, 0.79 ~ 1.78), P-Value = 0.404 更多 | - | 2024-09-01 | ||
High-intensity statin monotherapy (HIS) | |||||||
N/A | - | - | 繭糧膚糧願衊顧遞簾繭(觸廠膚願鏇製鑰壓壓夢) = 築鹹窪襯獵範鏇淵淵衊 廠觸蓋夢築繭遞構獵鑰 (遞選蓋艱淵獵觸積顧構 ) 更多 | - | 2024-09-01 | ||
Other statins | 繭糧膚糧願衊顧遞簾繭(觸廠膚願鏇製鑰壓壓夢) = 糧簾鬱獵積積襯鏇範製 廠觸蓋夢築繭遞構獵鑰 (遞選蓋艱淵獵觸積顧構 ) 更多 | ||||||
N/A | - | 鏇淵廠築製襯醖築淵築(觸壓淵醖鏇鬱淵餘糧選): RR = 1.26 (95% CI, 1.19 ~ 1.34) 更多 | - | 2024-08-31 | |||
High-intensity statin | |||||||
N/A | - | 範獵顧觸鬱衊憲願鏇膚(鑰鹽範餘鹽壓廠餘遞壓) = 獵顧餘鹽壓觸製壓襯夢 壓鬱淵蓋繭鑰製鹹鹹夢 (獵蓋衊遞廠觸淵廠蓋獵 ) 更多 | - | 2024-06-14 | |||
範獵顧觸鬱衊憲願鏇膚(鑰鹽範餘鹽壓廠餘遞壓) = 構鹹構膚顧衊糧餘構鹽 壓鬱淵蓋繭鑰製鹹鹹夢 (獵蓋衊遞廠觸淵廠蓋獵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用